India Neuromodulation Devices Market Outlook to 2028

India Neuromodulation Devices Market Overview

In the last five years, the India Neuromodulation Devices Market has grown exceptionally, this is reflected by the global neuromodulation devices market reaching a market size of USD 6 Bn in 2023 driven by increasing incidences of neurological disorders, including chronic pain, epilepsy, and depression, which require long-term treatment. Additionally, rising healthcare expenditure and increasing awareness of advanced medical technologies among healthcare professionals and patients are contributing to market expansion.

The key players dominating the Indian neuromodulation devices market include Medtronic, Abbott, Boston Scientific, Nevro Corp, and Liva Nova PLC. These companies have established strong market positions through a combination of innovative product offerings, strategic partnerships with hospitals and clinics, and extensive distribution networks across India.

In 2023, Medtronic announced the launch of its Vanta rechargeable neurostimulator in India, enhancing its portfolio of neuromodulation devices for chronic pain management. The Vanta system is designed to offer improved battery life and customizable therapy, addressing the growing demand for advanced pain management solutions in India.

The cities of Mumbai, Delhi, and Bengaluru dominate the neuromodulation devices market in India, primarily due to the concentration of top-tier hospitals and specialized neurological care centers in these regions. These cities also have a higher prevalence of neurological disorders due to urban lifestyles, increasing the demand for neuromodulation devices.

India Neuromodulation Devices Market Segmentation

The India Neuromodulation Devices Market is segmented by various factors including Product Type, Application, and Region.

By Product Type: The India Neuromodulation Devices Market is segmented by product type into Spinal Cord Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, and Other Neuromodulation Devices. In 2023, Spinal Cord Stimulators held a dominant market share of due to their widespread use in managing chronic pain conditions, which are highly prevalent in India. The increasing number of spinal surgeries and the preference for non-pharmacological pain management options have contributed to the dominance of this segment.

By Application: The market is segmented by application into Pain Management, Parkinson's Disease, Urinary and Fecal Incontinence, Epilepsy, and Other Neurological Disorders. In 2023, Pain Management accounted for the market share, driven by the high prevalence of chronic pain conditions and the growing preference for minimally invasive treatment options. Neuromodulation devices are increasingly favored for pain management due to their effectiveness and fewer side effects compared to traditional pharmacological treatments.

By Region: The India Neuromodulation Devices Market is segmented by region into North, South, East, and West. In 2023, the North region led the market with a share, driven by the presence of top-tier hospitals, a higher concentration of neurological specialists, and greater awareness of neuromodulation therapies. The North region's dominance is also supported by better healthcare infrastructure and government initiatives aimed at improving healthcare services in this area.

India Neuromodulation Devices Market Competitive Landscape

Company

Establishment Year

Headquarters

Medtronic

1949

Dublin, Ireland

Abbott

1888

Chicago, USA

Boston Scientific

1979

Marlborough, USA

Nevro Corp

2006

Redwood City, USA

Liva Nova PLC

2015

London, UK

Boston Scientific: In 2023, Boston Scientific introduced the Wave Writer Alpha spinal cord stimulator in India, which allows for multiple waveforms to be used in pain management therapy. This product has gained traction in the Indian market due to its ability to offer personalized pain relief, improving patient outcomes. Boston Scientific continues to expand its market share through innovative products and a strong distribution network.

Abbott: Abbott expanded its neuromodulation offerings in India with the launch of the Proclaim XR spinal cord stimulator in 2019. This device provides long-lasting pain relief with minimal maintenance, catering to the needs of chronic pain patients in India. Abbotts collaboration with leading Indian healthcare providers has enhanced the accessibility of its advanced neuromodulation therapies, strengthening its market presence.

India Neuromodulation Devices Market Analysis

Market Growth Drivers:

Increasing Prevalence of Neurological Disorders: India is witnessing a significant rise in the prevalence of neurological disorders, which is driving the demand for neuromodulation devices. As of 2024, 30 million people in India are affected by neurological conditions such as epilepsy, Parkinsons disease, and chronic pain, necessitating the use of advanced treatment options like neuromodulation devices.

Expanding Healthcare Infrastructure: The Indian governments focus on improving healthcare infrastructure is a major growth driver for the neuromodulation devices market. In 2024, the government allocated INR 64000 crore for healthcare infrastructure development under the Pradhan Mantri Ayushman Bharat Health Infrastructure Mission. This initiative aims to upgrade hospitals and healthcare facilities across the country, making advanced medical treatments more accessible.

Rising Investment in R&D: Significant investment in research and development by key players is propelling the growth of the neuromodulation devices market. In 2024, companies like Medtronic and Boston Scientific invested over INR 3,000 crore collectively in R&D, focusing on developing next-generation neuromodulation devices. These investments are expected to lead to the introduction of more advanced devices, driving market growth.

India Neuromodulation Devices Market Challenges

High Cost of Devices and Treatment: The high cost of neuromodulation devices and associated treatment procedures is a major challenge in the Indian market. As of 2024, the average cost of a spinal cord stimulator implant ranges between INR10 lakh, making it unaffordable for a large segment of the population. This cost barrier is a significant factor limiting market growth.

Regulatory Hurdles: The regulatory landscape for neuromodulation devices in India poses challenges for market growth. Companies face an average regulatory approval time of 18-24 months for new neuromodulation devices due to stringent requirements set by the Central Drugs Standard Control Organization (CDSCO). These delays hinder the timely availability of advanced therapies to patients.

India Neuromodulation Devices Market Government Initiatives

National Digital Health Mission (NDHM): Launched in 2023, the NDHM aims to create a digital health ecosystem in India, enabling better access to healthcare services, including neuromodulation therapies. By integrating electronic health records and telemedicine, the mission is expected to streamline the diagnosis and treatment processes, making it easier for patients to access neuromodulation treatments.

Pradhan Mantri Ayushman Bharat Health Infrastructure Mission: This initiative, ongoing through 2024, focuses on strengthening Indias healthcare infrastructure. With a budget allocation of INR 64000 crore in 2024, the mission includes the establishment of critical care units and integrated public health labs, which are crucial for diagnosing and managing neurological disorders.

India Neuromodulation Devices Future Market Outlook

The India Neuromodulation Devices Market is expected to witness robust growth through 2028, driven by continued advancements in technology, increasing adoption of neuromodulation therapies, and supportive government policies.

Future Market Trends

Rising Adoption of Closed- Loop Neuromodulation Systems: By 2028, the market is expected to see a significant increase in the adoption of closed-loop neuromodulation systems. These systems automatically adjust stimulation parameters based on real-time feedback from the patients nervous system, offering enhanced efficacy and personalized treatment. The growing focus on patient-specific therapies, coupled with advancements in sensor technology, will drive the adoption of these sophisticated systems.

Expansion of Neuromodulation in Psychiatry: The use of neuromodulation devices for psychiatric conditions, such as depression and obsessive-compulsive disorder (OCD), is expected to grow significantly by 2028. Clinical trials and pilot programs for deep brain stimulation (DBS) in treating refractory depression are already underway in India. As these trials yield positive results, neuromodulation is likely to become a mainstream treatment option in psychiatry.
Please Note: It will take 5-7 business days to complete the report upon order confirmation